High-resolution cerebral blood volume imaging in humans using the blood pool contrast agent ferumoxytol

Abstract

Cerebral blood volume maps are usually acquired using dynamic susceptibility contrast imaging which inherently limits the spatial resolution and signal to noise ratio of the images. In this study, we used ferumoxytol (AMAG Pharmaceuticals, Inc., Cambridge, MA), an FDA-approved compound, to obtain high-resolution cerebral blood volume maps with a steady-state approach in seven healthy volunteers. R2* maps (0.8 × 0.8 × 1 mm(3)) were acquired before and after injection of ferumoxytol and an intraindividual normalization protocol was used to obtain quantitative values. The results show excellent contrast between white and gray matter as well as fine highly detailed vascular structures. An average blood volume of 4% was found in the brain of all volunteers, consistent with prior literature values. A linear relationship was found between ferumoxytol dose (mg/kg) and ΔR2* (1/s) in gray (R(2) = 0.98) and white matter (R(2) = 0.98). A quadratic relationship was found in the sagittal sinus (R(2) = 0.98). The cerebral blood volume maps compare well with lower resolution dynamic susceptibility contrast-MRI and their use should improve the evaluation of small and heterogeneous lesions and facilitate intrapatient and interpatient comparisons.

Tissue Oxygen Saturation Mapping with Magnetic Resonance Imaging

“…In this study, CBV was mapped using a steady-state approach and iron oxide particles, which yielded accurate maps with high spatial resolution. This approach has recently become available 29,30 for human experiments and may also be replaced by a dynamic susceptibility contrast approach using a bolus of routinely used gadolinium. 31 Second, mqBOLD uses the total CBV instead of the deoxygenated blood volume.…”

Polyelectrolyte coating of ferumoxytol nanoparticles for labeling of dendritic cells

“…In previous studies, ferumoxytol has been used as a macrophage-imaging agent as well as a blood-pool agent with MRI [9][10][11]. However, ferumoxytol alone did not result in effective cell labeling [12].…”

Polymer film-nanoparticle composites as new multimodality, non-migrating breast biopsy markers

“…Iron oxide nanoparticles are also generally considered safe and are FDA-approved for treatment of anaemic patients with chronic kidney disease (via i.v. administration of significantly higher concentrations), as well as for use as MRI contrast agents [30][31][32][33][34][35]. Our preliminary in vitro cytotoxicity studies using NIH/3T3 (mouse fibroblast) cells coincubated with prototype markers show no toxicity in comparison to untreated controls.…”